Open in interactive viewer → charts, metric popovers & call review

Daré Finally Has a Product to Sell — and Roughly Six Months of Cash to Sell It With

The first real revenue line ($48,000) lands next to a 79% ninety-day drawdown, a 1.9-quarter runway, and the quiet retirement of the hormone-ring story that carried 2025.
DARE · Earnings Call · 2026-11-16

The Moment, and the Tape

Sabrina Johnson opened her prepared remarks with the line every decade-long biotech shareholder wants to hear: “For more than 10 years, Daré has been building towards this moment.” — Sabrina Johnson, Chief Executive Officer · 2026-11-16 Two commercial products, one in market since July and one en route to a mail-order pharmacy, two Phase II/III readouts due in 2027, and $60 million-plus of grant money that has kept dilution at bay. The tape disagrees violently. Daré's stock is down 79.3% over the last 90 trading days, with the last four sessions alone shedding 38% into this report — a collapse from a $2.07 peak in mid-July to roughly $0.43, against a market capitalization that now sits under $9 million. The full-history line is worse: down 99.9% from a 2015 peak. This is a company reporting its first commercially meaningful quarter from the floor of a drawdown, and the market has already voted on whether it believes the timeline.

Twelve Months of "This Month"

Here is the tension that matters. Daré has now promised DARE to PLAY dispensing three times.

We're proud to be leading the science, collaboration and purpose and are excited to begin making DARE to PLAY available through the 503B channel, which is on track for December.

Sabrina Johnson, President and CEO · 2025-11-13
That was November 2025. By May 2026 the language had moved to "dispensing is targeted for this summer," with the explanation that the 503B outsourcing facility partner was grinding through state-by-state licensure and had reached 28 registrations. Today the same 28 states appear, the product is "en route to Medvantx," and dispensing is again promised for "this month" — November. Third time. The Medvantx handoff and the Sildenafil Cream prescription backlog (182 office-based prescribers, scripts written across 48 states plus DC) are genuine progress markers, but they have been genuine progress markers for three calls running. Equally telling is the economics. Daré does not own the DARE to PLAY inventory: “That inventory belongs to that 503B facility... what we'll be booking is the net proceeds, net of all that.” — Sabrina Johnson, Chief Executive Officer · 2026-11-16 A $99-per-tube product, a claimed $2 billion total addressable market on 20 million women, and Daré books the residual after the compounding facility and the pharmacy take their cuts.

What Is Actually New: Flora, Amazon, and a Deliberate Refusal to Scale Fast

Flora Sync LF5 is the genuinely new thing. A non-prescription vaginal probiotic launched in July, it gave Daré its first direct-to-consumer revenue channel and, per management, orders from 27 states, its first provider-office reorder, and a 4.9-star rating across roughly 25 reviews. The strategic logic is that a clinician recommendation converts into an office purchase and then a repeat consumer buy — a loop the Health Hub and office-based providers are meant to close. The new channel is Amazon, where Flora Sync was selected for a seller recruitment program with availability targeted for early 2027, alongside two line extensions (Flora Renew, Flora Reset). That is a real, if distant, catalyst. But the same paragraph contains the constraint. Johnson explicitly declined the large national subscription telehealth platforms — the high-volume, low-price channels that could actually move units — citing a desire to "protect our pricing" and avoid concentration risk. It is a defensible brand decision and a terrible one for a company with 1.9 quarters of cash. Disciplined execution, repeated as a mantra, is here doing the work of an excuse.

What Went Quiet

The most informative fact on this call is a keyword that barely appeared. A year ago the marquee asset was DARE-HRT1, the estradiol/progesterone intravaginal ring riding the FDA's removal of menopause-therapy black box warnings — the subject of analyst questions in November 2025 and again in August 2026, when Johnson called it a product she "cannot move fast enough" on. Today it gets one clause, renamed DARE to RECLAIM, with availability "targeted for 2027." No analyst asked about it. The keyword momentum confirms the demotion: progesterone and estradiol are among the sharpest fallers in Daré's own vocabulary this quarter, and FDA approval — the entire 505(b)(2) rationale — has slid as well. In their place: Flora, outsourcing facility, Health Hub, office-based providers, Amazon. The portfolio narrative has been compressed into whatever can generate cash inside twelve months, because the balance sheet will not fund the rest.

The Cash Math and the GLP-1 Life Raft

“We ended the third quarter with approximately $11.5 million in cash and cash equivalents as of September 30, 2026, and working capital of approximately $3.2 million.” — MarDee Haring-Layton, Chief Financial Officer · 2026-11-16 Total revenue was $48,000. Cash runway, as measured off the latest filing, sits at 1.9 quarters, and the leverage picture is grim: liabilities at 102.5% of assets, still below the 146% peak but with no visible bridge. R&D expense of $242,000 is down 83% year over year — framed carefully as the arithmetic of nondilutive grants rather than a company that cannot afford its own trials. In May the CFO-equivalent answer to the runway question was blunt: “we will need to raise. We don't have 12 months of capital from that perspective.” — Sabrina Johnson, Chief Executive Officer · 2026-05-14 That is the setup, so watch what Daré reaches for. Mid-call, Johnson surfaced DARE-IDDS, the programmable implant platform behind DARE-LARC1, and volunteered that it is in exploratory collaboration discussions across "obesity, diabetes, hormone therapies and neurologic disease, including potential applications with GLP-1 medicines." A preclinical delivery technology with no partner, no data disclosure, and no disclosed terms, being attached to the single hottest capital-market theme in healthcare. That is not a coincidence; it is a company that needs a narrative big enough to fund a raise, and the GLP-1 wave — visible across this quarter's reporting cohort of consumer-health and metabolic names — is the only wave big enough. Daré is no longer a pipeline story or a menopause story. It is a cash-conversion story with roughly two quarters to prove that $48,000 becomes something, and a stock that has already priced in the alternative.